Juan Sierra-Madero

Summary

Publications

  1. ncbi Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico
    Juan Sierra-Madero
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City
    J Acquir Immune Defic Syndr 53:582-8. 2010
  2. ncbi Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico
    Alondra Lopez-Martinez
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    J Acquir Immune Defic Syndr 59:155-60. 2012
  3. ncbi Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico
    Brenda Crabtree-Ramírez
    Department of Infectious Diseases, HIV AIDS Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico
    AIDS Res Hum Retroviruses 26:373-8. 2010
  4. ncbi Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment
    Patricia Cornejo-Juárez
    Departamento de Enfermedades Infecciosas, Instituto Nacional de Cancerologia, Mexico City, Mexico
    Arch Med Res 34:64-9. 2003

Collaborators

Detail Information

Publications4

  1. ncbi Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico
    Juan Sierra-Madero
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City
    J Acquir Immune Defic Syndr 53:582-8. 2010
    ..To compare the efficacy of efavirenz (EFV) vs lopinavir/ritonavir (LPV/r) in combination with azidothymidine/lamivudine in antiretroviral therapy naive, HIV+ individuals presenting for care with CD4 counts <200/mm...
  2. ncbi Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico
    Alondra Lopez-Martinez
    Department of Infectious Diseases, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
    J Acquir Immune Defic Syndr 59:155-60. 2012
    ..The efficacy of antiretroviral therapy (ART) has been established through clinical trials (CTs). However, selection bias and differences can limit their applicability to the general population...
  3. ncbi Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico
    Brenda Crabtree-Ramírez
    Department of Infectious Diseases, HIV AIDS Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico
    AIDS Res Hum Retroviruses 26:373-8. 2010
    ..Implementation of NGP for HAART access in a specialized care setting in Mexico resulted in an excellent virologic response. Younger age was a significant risk factor for VF...
  4. ncbi Metabolic acidosis and hepatic steatosis in two HIV-infected patients on stavudine (d4T) treatment
    Patricia Cornejo-Juárez
    Departamento de Enfermedades Infecciosas, Instituto Nacional de Cancerologia, Mexico City, Mexico
    Arch Med Res 34:64-9. 2003
    ..It is important to report serious adverse events in commercially released drugs to know prevalence in an exposed population. Physicians should be aware of risk and early signs of this serious adverse event...